Syndromes of hematophagocytosis in patients of pediatric intensive care units (literature review)
Hemophagocytic lymphohistiocytosis (hemophagocytic syndrome, HLH, HPS) is the group of severe life-threatening and hardly diagnosing conditions caused by the immune dysregulation because of systemic inflammatory response with non-controlled proliferation and activation of T-cells, monocytes and macr...
Saved in:
| Main Authors: | N. N. Abramova, K. E. Belozerov, G. V. Kondratiev, Yu. S. Aleksandrovich, M. M. Kostik |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2023-07-01
|
| Series: | Вестник анестезиологии и реаниматологии |
| Subjects: | |
| Online Access: | https://www.vair-journal.com/jour/article/view/837 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases
by: Canan Özlü, et al.
Published: (2021-12-01) -
CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
by: E. I. Alexeeva, et al.
Published: (2014-03-01) -
EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
by: Maksim Sergeyevna Eliseev, et al.
Published: (2014-03-01) -
Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2020-08-01) -
CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-09-01)